Coadministration of Lopinavir/Ritonavir and Rifampicin in HIV and Tuberculosis Co-Infected Adults in South Africa

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Murphy, Richard A ^a   Marconi, Vincent C ^b   Gandhi, Rajesh T ^c   Kuritzkes, Daniel R ^d   Sunpath, Henry ^e  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e MCCORD HOSPITAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE PLUS ZIDOVUDINE; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; ISONIAZID PLUS RIFAMPICIN; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; UNCLASSIFIED DRUG;

ADULT; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG FATALITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRANSAMINASEMIA; MALE; MIXED INFECTION; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; SOUTH AFRICA; TOXIC HEPATITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREND STUDY; TUBERCULOSIS; VIRUS LOAD;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIBIOTICS, ANTITUBERCULAR; CHILD; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; KAPLAN-MEIER ESTIMATE; LOPINAVIR; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIFAMPIN; RITONAVIR; SOUTH AFRICA; TIME FACTORS; TUBERCULOSIS; YOUNG ADULT;

EID: 84866978266     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044793     Document Type: Review

References (16)

1. Murphy RA, Sunpath H, Lu Z, Chelin N, Losina E, et al. (2010) Outcomes after virologic failure of first-line ART in South Africa. AIDS 24: 1007-1012.
2. (2010) Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector.: WHO.
3. la Porte CJ, Colbers EP, Bertz R, Voncken DS, Wikstrom K, et al. (2004) Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 48: 1553-1560.
4. (2011) Managing Drug Interactions in the Treatment of HIV-related Tuberculosis.
5. Burman WJ, Gallicano K, Peloquin C (1999) Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Clin Infect Dis 28: 419-429; quiz 430.
6. Burger DM, Agarwala S, Child M, Been-Tiktak A, Wang Y, et al. (2006) Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. Antimicrob Agents Chemother 50: 3336-3342.
7. (2004) South African National Antiretroviral Treatment Guidelines. South African Department of Health.
8. Nijland HM, L'Homme RF, Rongen GA, van Uden P, van Crevel R, et al. (2008) High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS 22: 931-935.
9. L'Homme RF, Nijland HM, Gras L, Aarnoutse RE, van Crevel R, et al. (2009) Clinical experience with the combined use of lopinavir/ritonavir and rifampicin. AIDS 23: 863-865.
10. Frohoff C, Moodley M, Fairlie L, Coovadia A, Moultrie H, et al. (2011) Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment. PLoS One 6: e17273.
11. Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS, (2007) HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr 45: 4-8.
12. Team DT, Mugyenyi P, Walker AS, Hakim J, Munderi P, et al (2010) Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 375: 123-131.
13. Decloedt EH, Maartens G, Smith P, Merry C, Bango F, et al. (2012) The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy. PLoS One 7: e32173.
14. Matteelli A, Villani P, Carvalho AC, El-Hamad I, Cusato M, et al. (2012) Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy. J Antimicrob Chemother.
15. Boulanger C, Hollender E, Farrell K, Stambaugh JJ, Maasen D, et al. (2009) Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis 49: 1305-1311.
16. Mena A, Vazquez P, Castro A, Lopez S, Bello L, et al. (2011) Clinical experience of raltegravir-containing regimens in HIV-infected patients during rifampicin-containing treatment of tuberculosis. J Antimicrob Chemother. England. 951-952.